financetom
Business
financetom
/
Business
/
Masimo smartwatches infringe Apple design patents, US jury says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Masimo smartwatches infringe Apple design patents, US jury says
Nov 3, 2024 12:04 PM

Oct 25 (Reuters) - Apple ( AAPL ) convinced a federal

jury on Friday that health monitoring tech company Masimo's ( MASI )

smartwatches infringe two of its design patents.

The jury, in Delaware, agreed with Apple ( AAPL ) that Masimo's ( MASI ) W1

and Freedom watches and chargers willfully violated Apple's ( AAPL )

patent rights in smartwatch designs, awarding the tech giant

$250 in damages. Apple's ( AAPL ) attorneys told the court the "ultimate

purpose" of its lawsuit was to win an injunction against sales

of Masimo's ( MASI ) smartwatches after an infringement ruling.

The jury also determined that Masimo's ( MASI ) watches did not

infringe Apple ( AAPL ) patents covering smartwatch inventions that the

tech giant had accused Masimo ( MASI ) of copying.

Masimo ( MASI ) said in a statement that the company appreciated the

jury's verdict "in favor of Masimo ( MASI ) and against Apple ( AAPL ) on nearly

all issues," and that the decision only applied to a

"discontinued module and charger."

"Apple ( AAPL ) primarily sought an injunction against Masimo's ( MASI )

current products, and the jury's verdict is a victory for Masimo ( MASI )

on that issue," Masimo ( MASI ) said.

Apple ( AAPL ) said in a statement that it was "glad the jury's

decision today will protect the innovations we advance on behalf

of our customers."

Irvine, California-based Masimo ( MASI ) accused Apple ( AAPL ) of hiring

away its employees and stealing its pulse oximetry technology

after discussing a potential collaboration. Masimo ( MASI ) convinced the

U.S. International Trade Commission last year to block imports

of Apple's ( AAPL ) Series 9 and Ultra 2 smartwatches after the

commission found that their technology for reading blood oxygen

levels infringed Masimo's ( MASI ) patents.

Apple ( AAPL ) has appealed the decision and resumed selling the

watches after removing the technology. The tech giant

countersued Masimo ( MASI ) for patent infringement in 2022, alleging

that Masimo ( MASI ) copied Apple Watch features to use in its

smartwatches.

Apple ( AAPL ) also accused Masimo ( MASI ) of using lawsuits at the ITC

and in California to "make way for Masimo's ( MASI ) own watch." Masimo ( MASI )

said Apple's ( AAPL ) patent lawsuit was "retaliatory" and "an attempt to

avoid the court in which the parties have been litigating their

dispute."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Novo Nordisk's India Executives Push for Wegovy Launch in 2025
Market Chatter: Novo Nordisk's India Executives Push for Wegovy Launch in 2025
Dec 3, 2024
07:35 AM EST, 12/03/2024 (MT Newswires) -- Novo Nordisk's ( NVO ) India-based executives have proposed moving up the launch of the weight-loss drug Wegovy in the country to 2025, instead of 2026 as planned, due to concerns about falling behind Eli Lilly's ( LLY ) Mounjaro, Reuters reported Tuesday, citing two sources familiar with the matter. Eli Lilly (...
Foran Mining Provides Construction Update for McIlvenna Bay Project in Saskatchewan
Foran Mining Provides Construction Update for McIlvenna Bay Project in Saskatchewan
Dec 3, 2024
07:30 AM EST, 12/03/2024 (MT Newswires) -- Foran Mining ( FMCXF ) said Tuesday that it continues to advance the construction of the McIlvenna Bay copper-zinc-gold-silver project in Saskatchewan. The company outlined the progress of work at the project, including the rebar installation for the process plant building, installation of the semi-autogenous grinding mill shell, completion of under-pad earthworks for...
Oncolytics Biotech Competes Safety Phase Enrollment for GOBLET Trial's Pancreatic Cancer Cohort
Oncolytics Biotech Competes Safety Phase Enrollment for GOBLET Trial's Pancreatic Cancer Cohort
Dec 3, 2024
07:34 AM EST, 12/03/2024 (MT Newswires) -- Oncolytics Biotech ( ONCY ) on Tuesday said that the Data Safety Monitoring Board (DSMB) has recommended continued enrollment in Cohort 5 of the GOBLET study after reviewing initial safety data. Enrollment in the cohort will resume pending final approval from the Paul Ehrlich Institute, Germany's medical regulatory body. Additional updates are expected...
Mirion Technologies Unveils 2028 Outlook; Approves $100 Million Share Repurchase
Mirion Technologies Unveils 2028 Outlook; Approves $100 Million Share Repurchase
Dec 3, 2024
07:33 AM EST, 12/03/2024 (MT Newswires) -- Mirion Technologies ( MIR ) on Tuesday provided 2028 financial targets, projecting revenue of approximately $1.1 billion with 6% to 8% organic growth and an adjusted earnings before interest, taxes, depreciation, and amortization margin of 30%. For 2025, the company said it anticipates revenue growth of 4% to 6%, factoring in a 150...
Copyright 2023-2026 - www.financetom.com All Rights Reserved